ABVC BioPharma, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
ABVC BioPharma, Inc. (ECOC) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents of $531.15 thousand as of 2019-02-08, per its 10-Q filed 2022-11-14.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents · last filed 2022-11-14
- 2019-02-08: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $531.15K.
- 2018-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents $636.67K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents |
|---|---|
| 2019-02-08 | $531.15K 10-Q · filed 2022-11-14 |
| 2018-12-31 | $636.67K 10-K · filed 2019-04-15 |